

SELECT BOTANICAL

DIPOTASSIUM GLYCYRRHIZINATE

Technical-Scientific report

GENERAL INFORMATION

Select Botanical, SL manufactures highest quality extracts following strictest Quality Management System in compliance with the "Good Manufacturing Practices" requirements, carrying on the last manufacturing steps in classified areas (Clean Rooms).

Select Botanical, SL assures the traceability with rigorous analysis from raw material to finished product.

Definition:

20 β -Carboxy -11-oxo-30-norolean-12-en-3 β -yl-2-O- β -D-glucopyranosyl- α -D-glucopyranosiduronic acid dipotassium salt.

SPECIFICATIONS/ TECHNICAL CHARACTERISTICS

Description:	White or almost white powder
Appearance of solution:	Clear
pH (1 % in water):	5-6
Loss on drying:	\leq 5.0% w/w
Residue of ignition:	\leq 21.0 % w/w
Heavy metals:	\leq 10 ppm
Assay (UV/Vis):	\geq 99.0 %

INFORMATION ABOUT MANUFACTURING PROCESS

Dipotassium Glycyrrhizinate is obtained from the licorice root (*Glycyrrhiza glabra* L.) by extraction and purification methods.


PRODUCT PROPERTIES

- sb** Solubility: Soluble in water, glycerin, propylene glycol and hydroalcoholic mixtures.
Not soluble in butylene glycol and polyethylene glycols of low molecular weight.
Not soluble in oily phases (Caprylic/Capric triglycerides).

REGULATORY INFORMATION AND DESCRIPTION

CAS: 68797-35-3
EINECS: 272-296-1
INCI/ UE: Dipotassium Glycyrrhizate

Structure:



Molecular formula: C₄₂H₆₀O₁₆K₂

Relative molecular weight: 899,142

DIPOTASSIUM GLYCYRRHIZINATE

Technical -Scientific report

PROPERTIES

Dipotassium Glycyrrhizinate exhibits anti-inflammatory activity due to Glycyrrhizic Acid, the active component.

Glycyrrhizic Acid presents:

- sb Anti-inflammatory activity: inhibits the activity of the phospholipase A₂ that plays an important role in various inflammatory processes. Moreover, Glycyrrhizic Acid inhibits cyclooxygenase activity and the formation of prostaglandins. Also, inhibits in vitro the hyaluronidase, which is active during inflammation.

PRODUCT APPLICATIONS

Properties:

- sb Anti-inflammatory.
- sb Smoothing and calming.
- sb Skin conditioning.
- sb Sebum regulating.

Indications:

- sb Indicated in the treatment of inflammations skin as wounds, eczema and burns.
- sb Indicated in the treatment of gingival inflammations. Hygiene and dental protection.
- sb Care of sensitive, fragile and irritable skin.
- sb Scalp care.

Undesirable effects:

There are neither reported toxic effects nor intolerance phenomenon to normal use doses.

Dosage and administration:

Topical use:

Dipotassium Glycyrrhizinate may be found formulated in creams, emulsions, lotions, shampoos and toothpastes, among others.

Its solubility permits its use in cosmetic preparations with aqueous base

BIBLIOGRAPHY AND OTHER REFERENCES SOURCES

1. Chandler, R.F., Keller, K, Smet, D. "Glycyrrhiza glabra". Adverse effects of Herbal Drugs, Vol. 3. Springer-Verlag. 1997.
2. Okimasu, E, Moromizato, Y., Watanabe S. "Inhibition of phospholipase A₂ and platelet aggregation by glycyrrhizin, an antiinflammation drug". Acta Med. Okayama 37, (5), 385-391 (1983).
3. Dweck, A.C. " Botanicals-Research of Actives". Cosmetics & Toiletries magazine. Vol 111, January 1996.
4. Furuya, T., Yamagata, S., Shimoyama, Y., Fujihara, M. " Biochemical characterization of glycyrrhizin as an effective inhibitor for hyaluronidases from bovine tests". Biol. Pharm. Bull. 1997. Sep;20 (9):973-7.
5. Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanin D. A history of the therapeutic of liquorice in Europe. Journal of Ethnopharmacology, Volume 99, Issue 3, 14 July 2005, Pages 317-324.



Information contained in this Technical Scientific Report is believed to be accurate and is offered in good faith for the benefit of the user of the product. Select Botanical, SL cannot assume any liability or risk involved in the use of its products since the conditions of the use are beyond our control. The user of our product is responsible for compliance with all legal regulations applying to the use of our products, including patent laws.

Revision: 01
January 2014